Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 158

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

FDA Approval Summary: Palbociclib for Male Patients with Metastatic Breast Cancer

Wedam, Suparna, Fashoyin-Aje, Lola, Bloomquist, Erik, Tang, Shenghui, Sridhara, Rajeshwari, Goldberg, Kirsten B., Theoret, Marc R., Amiri-Kordestani, Laleh, Pazdur, Richard, Beaver, Julia A. · 2020 · Clinical Cancer Research

Abstract

On April 4, 2019, the FDA approved a supplemental new drug application for palbociclib (IBRANCE), to expand the approved indications in women with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer (MBC) in combination with an aromatase inhibitor or fulvestrant, to include men. Palbociclib was first approved in 2015 for use in combination with letrozole for the treatment of estrogen receptor–positive, HER2-negative advanced breast cancer as initial endocrine-based therapy in postmenopausal women and subsequently in 2016 in combination with fulvestrant in women with HR-positive, HER2-negative advanced breast cancer with disease progression following endocrine therapy. The current approval was primarily based on the results of the PALOMA-2 and PALOMA-3 trials and, supported by real-world data from electronic health records and insurance claims. To support the safety evaluation in male patients, data from two phase I studies with palbociclib and safety information from the global safety database, were also reviewed. This article summarizes FDA decision-making and data supporting the approval of palbociclib for the treatment of male patients with HR-positive, HER2-negative advanced or MBC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-19-2580

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 158

Metadata

Authors
Wedam, S., Fashoyin-Aje, L., Bloomquist, E., Tang, S., Sridhara, R., Goldberg, K. B., Theoret, M. R., Amiri-Kordestani, L., Pazdur, R., & Beaver, J. A.
Venue
Clinical Cancer Research
Published
2020-03-13
Volume
26
Issue
6
Pages
1208-1212
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2982183961
Cited by
158
References
1
FWCI
10.87
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: FDA Approval Summary: Palbociclib for Male Patients with Metastatic Breast Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-19-2580
The paper
Wedam, S., Fashoyin-Aje, L., Bloomquist, E., Tang, S., Sridhara, R., Goldberg, K. B., Theoret, M. R., Amiri-Kordestani, L., Pazdur, R., & Beaver, J. A. (2020). FDA Approval Summary: Palbociclib for Male Patients with Metastatic Breast Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-19-2580

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.